About quince therapeutics inc - QNCX
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
QNCX At a Glance
Quince Therapeutics, Inc.
611 Gateway Boulevard
South San Francisco, California 94080
| Phone | 1-415-910-5717 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -83,979,000.00 | |
| Sector | Health Technology | Employees | 38 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
QNCX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.352 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.11 |
QNCX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,209,973.684 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
QNCX Liquidity
| Current Ratio | 0.53 |
| Quick Ratio | 0.53 |
| Cash Ratio | 0.411 |
QNCX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -76.419 |
| Return on Equity | N/A |
| Return on Total Capital | 487.032 |
| Return on Invested Capital | -1,772.27 |
QNCX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -107.122 |
| Total Debt to Total Assets | 19.727 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -1.914 |